Introduction
Historically, as the penicillin molecule was chemically modified to extend its antibacterial spectrum, the resultant antibiotic lost potency against organisms susceptible to narrower spectrum drugs of this class. Carbenicillin and ticarcillin are two examples of such penicillins. Both possess activity against Pseudomonas aeruginosa but are weakly active against various Gram-positive and other fastidious organisms. In contrast to these two antipseudomonas penicillins, azlocillin and mezlocillin exemplify the new broad spectrum penicillins that retain activity against many fastidious organisms. This report reviews the in-vitro studies that have evaluated azlocillin.
In-vitro spectrum and potency

Fastidious Gram-negative organisms
Azlocillin, like mezlocillin, is highly active against ampicillin-susceptible Haemophilus infiuenzae and penicillin-susceptible neisseriae. Most strains of these organisms are inhibited by 0-5 mg/1 or less of either drug. Azlocillin and mezlocillin are as active as penicillin G against penicillin-susceptible neisseria and four-fold more active than either carbenicillin or ticarcillin (Figure l(a) ) Wise et a!., 1978; Gootz, Sanders & Sanders, 1979; Verbist, 1979; Baker, Thomsberry & Jones, 1980) . Both azlocillin and mezlocillin are two-fold more active than ampicillin and four-to eight-fold more active than carbenicillin or ticarcillin against ampicillin-susceptible H. infiuenzae (Figure l(b) ) Wise et al., 1978; Bywater, Holt & Reeves, 1979; Gootz el al, 1979; Verbist, 1979; Baker el al, 1980; Sanders, 1982) . Due to 21 their /J-lactamases, penicillin-resistant Neisseria gonorrhoeae and ampicillin-resistant H. influenzae are not highly susceptible to any of the penicillins (Wise et al, 1978; Bywater et al., 1979; Gootz et al., 1979; Baker et al., 1980; Sanders, 1982) .
Gram-positive organisms
Streptococci are generally very susceptible to azlocillin in vitro, most strains of nonenterococcal streptococci are inhibited by 10mg/l or less. Although less active than either penicillin G or ampicillin, azlocillin and mezlocillin are eight-fold more active than carbenicillin or ticarcillin against these streptococci (Figure l(c) ) Basker, Edmondson & Sutherland, 1979; Bywater et al., 1979; Gootz et al., 1979; Sanders, 1982) . The activity of azlocillin against group D streptococci is similar to that of mezlocillin and ampicillin with over 80% of strains inhibited by 4 mg/1 or less. Ticarcillin and carbenicillin are essentially inactive against this organism at similar concentrations (Basker et al., 1979; Bywater et al., 1979; White et al, 1979; Barry et al., 1980) . Azlocillin is active against penicillin-susceptible staphylococci but not active against penicillin-or methicillin-resistant staphylococci. In tests with penicillinsusceptible staphylococci, the activity of azlocillin and mezlocillin is less than penicillin G but somewhat greater than carbenicillin or ticarcillin (Figure l(d) ) (Basker et al, 1979; Bywater et al, 1979; Barry et al, 1980; Sanders, 1982) .
Obligate anaerobes
Azlocillin, like mezlocillin, is as active as carbenicillin or ticarcillin against Bacteroides fragilis and other Gram-negative anaerobes. At least 80% of strains are inhibited by 64mg/l or less of either ureidopenicillin (Sutter & Finegold, 1976; Wise et al., 1978; Basker et al., 1979; Thadepalli et al., 1979; Fass, 1980) . Against Gram-positive anaerobes, the activity of azlocillin and mezlocillin surpasses that of either carbenicillin or ticarcillin, most Gram-positive anaerobes being inhibited by 16 mg/1 or less (Sutter & Finegold, 1976; Basker et al., 1979; Thadepalli et al., 1979; Fass, 1980) .
Enterobacteriaceae
Azlocillin is less active than mezlocillin against Enterobacteriaceae that are intrinsically susceptible to ampicillin. This includes strains of Escherichia coli, shigellae, salmonellae and Proteus mirabilis. Most ampicillin-susceptible strains of these organisms are inhibited by 8 mg/1 or less of azlocillin. None of the antipseudomonas penicillins is highly active against /f-lactamase producing strains of these organisms that are ampicillin-resistant (Basker et al., 1979; Bywater et al., 1979; Gootz et al., 1979; Verbist, 1979; White et al., 1979; Wise & Andrews, 1982) .
Among the Enterobacteriaceae that are usually resistant to ampicillin, most are susceptible to mezlocillin at 64 mg/1. These include indole-positive proteus, providencia, citrobacter, serratia, klebsiella and enterobacter. The activity of mezlocillin against indole-positive proteus is comparable to carbenicillin and ticarcillin and four-fold greater than azlocillin. However, mezlocillin is more active than carbenicillin, ticarcillin or azlocillin against the other genera of these Enterobacteriaceae (Figure 2 (a)-(c))-Except for the klebsiellae, strains of these genera that are resistant to carbenicillin due to the production of a /Mactamase are usually also resistant to mezlocillin, azlocillin and ticarcillin Wagner et al, 1978; Basker et al., 1979; Bywater et al., 1979; Gootz et al., 1979; White et al, 1979; Barry et al, 1980; Fass, 1980; Wise & Andrews, 1982) .
Pseudomonas
Azlocillin is highly active against Ps. aeruginosa. In most studies published to date, over 80% of strains have been inhibited by azlocillin at concentrations of 64 mg/1 or less (Table I ). This antipseudomonal activity is four-fold greater than either mezlocillin or ticarcillin and eight-fold greater than carbenicillin (Figure 2(d) ) (Bywater et al., 1978; Chattopadhyay & Hall, 1979; Coppens & Klastersky, 1979; Verbist, 1979; Barry et al., 1980; Fass, 1980; Machka, Dickert & Braveny, 1980; Perea et al., 1980; Wise & Andrews, 1982) . Strains resistant to carbenicillin due to the production of a /Mactamase are also usually resistant to azlocillin, mezlocillin and ticarcillin. This is due to the instability of these four penicillins to plasmid-mediated /3-lactamases found in Pseudomonas. The influence of these enzymes on the organism's susceptibility to penicillins is best illustrated by the work of Jacoby & Sutton (1979) . These investigators introduced various plasmids coding for /Mactamase into the same (Stewart & Bodey, 1977; Bywater et al., 1978; Perea et al., 1980; Wise & Andrews, 1982) . Azlocillin is also more active than carbenicillin, ticarcillin or mezlocillin against other species of Pseudomonas and non-fermentative Gram-negative bacilli. At 64 mg/1 or less, azlocillin inhibits the majority of strains of these organisms Barry et al, 1980; Fass & Barnishan, 1980) .
Bactericidal activity
Azlocillin is bactericidal for susceptible strains. Like many other inhibitors of cell wall biosynthesis, azlocillin binds to numerous penicillin-binding proteins, however, its primary morphologic effect is filamentation-an effect which suggests that penicillinbinding protein 3 is the major target of the drugs within the bacterial cell. This is not unique to these new ureidopenicillins as filamentation is also the primary effect of carbenicillin, ticarcillin, cephalexin, and many so-called 'second' and 'third generation' cephalosporins (Zimmerman & Stapley, 1976; Tomasz, 1979; Zimmermann, 1980; Curtis, 1981; Greenwood & Eley, 1982) . The lethality of this effect has been well established (Curtis et al., 1979; Spratt, 1980; Zimmermann, 1980; Metzger, 1982) . Most filaments rapidly develop cellular defects and blebs and either lyse or lose viability without immediate lysis.
The bactericidal effects of azlocillin, in comparison with other penicillins, can be readily demonstrated in quantitative tests with both Gram-positive and Gram-negative bacteria. As shown in Figure 3 , both azlocillin and mezlocillin are bactericidal for Klebsiella pneumoniae, a genus highly resistant to carbenicillin and ticarcillin. The bactericidal activity of azlodllin and mezlocillin against Ps. aeruginosa can also be demonstrated in similar tests. As shown in Figure 4 , the initial rate of killing by azlodllin, mezlocillin, carbenicillin and ticardllin is similar against a carbenicillinsusceptible Ps. aeruginosa. However, between 8 and 24 h regrowth occurs in each drug. When the surviving cells recovered at 24 h are retested for their susceptibility to the four penicillins, a variety of results can be observed. With this particular strain, no change in susceptibility was detectable after 24 h exposure to azlociUin, mezlocillin or ticarcillin. However after exposure to carbenicillin, the susceptibility of the strain decreased four-to eight-fold for all of the drugs (Table III) . Thus, the lack of a complete bactericidal effect on this strain by azlociUin, mezlodllin or ticarcillin was not due to selection of a resistant sub-population. Regrowth in carbenidllin, however, was due to such a selection process. In bactericidal tests like these with other strains of Ps. aeruginosa, the extent of killing over 24 h varies from strain to strain with regrowth occurring in some but not all tests. This regrowth appears to Teflect the heterogeneity of Ps. aeruginosa in its response to the penicillins rather than any specific differences between the drugs. Results vary greatly from strain to strain and show no consistent pattern for any particular drug.
Factors influencing activity
The in-vitro activity of azlociUin, as with mezlocillin, is not greatly influenced by the test medium utilized or pH of the test medium. In the few instances where a pH effect has been observed, the activity of both drugs increased with alkalinization (Bodey & Pan, 1977; Stewart & Bodey, 1977; Wagner et al. 1978; Bywater et al., 1979) . Addition of up to 50% serum to the test medium has no consistent effect on the activity of these two drugs Bywater et al., 1979) . •From Figure 4 .
The in-vitro activity of azlocillin, like that of mezlocillin, is not greatly influenced by inoculum size in tests with most Gram-positive organisms and /Mactamase negative strains of fastidious Gram-negative organisms. However, the activity of each drug decreases with increases in the inoculum in tests with penicillin-resistant N. gorwrrhoeae, ampicillin-resistant H. influenzae, certain Enterobacteriaceae, and Ps. aeruginosa. This inoculum effect is similar to that observed with other penicillins and cephalosporins and is most pronounced in tests with Ps. aeruginosa (Bodey & Pan, 1977; Wagner el al, 1978; Basker et al, 1979; Gootz et al, 1979; Corrado, Landesman & Cherubin, 1980) . The influence of inoculum size on the antipseudomonas activity of four penicillins is illustrated in Table IV . Increasing the inoculum from 10 3 to 10 5 cfu/ml has little effect on the activity of azlocillin, mezlocillin, ticarcillin or carbenicillin. However, increasing the inoculum further to 10 7 cfu/ml significantly diminishes the activity of each drug. The average fold increase in MIC as the inoculum is increased from 10 5 to 10 7 cfu/ml is 128 for azlocillin, 64 for mezlocillin, 64 for ticarcillin and 32 for carbenicillin. It has been suggested that the greater inoculum effect observed for azlocillin in comparison to carbenicillin or ticarcillin is due to azlocillin's greater susceptibility to inactivation by the chromosomal /Mactamase of this organism (Basker et al., 1979; White, Comber & Sutherland, 1980) . This explanation seems unlikely since a number of cephalosporins that are resistant to hydrolysis by this /Mactamase also show a large inoculum effect (Corrado et al., 1980) . Rather, from Table FV , it appears that the greater inoculum effect of azlocillin is due solely to this drug's lower MICs against small inocula in Table IV . Effect of inoculum size on the antipseudomonas activity of four penicillins Minimal inhibitory concentration (mg/1) with inoculum of: 10 3 cfu/ml 10 5 cfu/ml 10 7 cfu/mlt Azlocillin Mezlocillin Ticarcillin Carbencillin
•Range of values observed in tests with five strains. fViable organisms were recoverable from tubes containing 800 mg/1 of each of the four penicillins.
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comparison to ticarcillin or carbenicillin. Thus, the mathematical ratio that is used to measure the inoculum effect (i.e. MIC with large inocula/MIC with small inocula) should be directly proportional to a drug's potency against small inocula. Finally, it should be noted in Table IV that none of the four drugs is active in vitro at concentrations achievable in the serum of humans when a large inoculum is employed. Whether this represents a potential clinical problem or merely reflects an artifact of testing too many cells in a closed in-vitro system is unknown.
Interactions with aminoglycosides
Numerous in-vitro studies have demonstrated the ability of azlocillin and mezlocillin to interact syneTgistically with the aminoglycosides against enterococci (White el al., 1979; Sanders, 1982) , many genera of Enterobacteriaceae Farrell, Wilks & Drasar, 1979; Kurtz et al. 1981; Zinner et al, 1981) and Ps. aeruginosa Bywater et al., 1979; Farrell et al., 1979; Gootz et al., 1979; White et al, 1979; Perea et al., 1980; Kurtz et al., 1981; Zinner et al, 1981; Scribner et al, 1982) . In general, synergy between azlocillin or mezlocillin and the aminoglycosides is most likely to occur in tests with strains susceptible to each drug. However, it also occurs in tests with some strains resistant to the aminoglycoside. Synergy is less likely to occur in tests with strains highly resistant to azlocillin or mezlocillin and does not occur in tests with strains resistant to both the penicillin and the aminoglycoside in the combination. In tests with Ps. aeruginosa, synergy between azlocillin and an aminoglycoside can be demonstrated with strains for which no synergy occurs between carbenicillin or ticarcillin and the aminoglycoside. The ability of azlocillin to interact synergistically with an aminoglycoside can also be demonstrated in an experimental infection model in rats. In this model, rats are given a lethal intraperitoneal challenge of Ps. aeruginosa and one hour later are treated with azlocillin, tobramycin or azlocillin plus tobramycin. The number of surviving animals Table V is determined 24 h postchallenge and the dose required to protect 50% of animals from death (PD 50 ) is calculated for each drug when administered alone. Since the doseresponse curve for each drug alone is not linear on an arithmetic scale in this model, a combination is considered synergistic if there is at least 50% protection when each drug is administered at a dose below the 95% confidence level for the PD 50 of each drug alone. As shown in Table V , a combination of 400 mg/kg of azlocillin and 0-5 mg/kg tobramycin fulfilled the criterion for synergy in this model. Subsequent studies revealed that this same synergy could be demonstrated when (i) the two drugs were administered simultaneously at 1 h postchallenge, (ii) azlocillin was administered 1 h postchallenge and tobramycin was administered 2 h postchallenge, or (iii) tobramycin was administered 1 h postchallenge and azlocillin was administered 2 h postchallenge. Thus, it does not appear that drug timing or dose sequencing has a major effect on this synergy.
